189 related articles for article (PubMed ID: 25066760)
41. [Increase in peripheral and liver infiltrating regulatory T cells favors development of primary hepatocellular carcinoma].
Wang SY; Fu JL; Lv JY; Chen LM; Lv S; Wang FS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Jun; 27(6):668-70. PubMed ID: 21651872
[TBL] [Abstract][Full Text] [Related]
42. High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma.
Duan XY; Pan Q; Yan SY; Ding WJ; Fan JG; Qiao L
BMC Gastroenterol; 2014 Nov; 14():195. PubMed ID: 25410681
[TBL] [Abstract][Full Text] [Related]
43. [Clinical significance of regulatory T cells proportion in the peripheral blood and tumor tissue in primary hepatocellular carcinoma].
Li SP; Peng QQ; Ding T; Xu J; Zhang CQ; Feng KT; Li JQ
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):523-7. PubMed ID: 19062720
[TBL] [Abstract][Full Text] [Related]
44. [Impact of novel negative immunoregulatory dendritic cells on regulatory T cells in cardiac allograft recipient rats].
Zheng DH; Shi BY; Zou YP; Cai M; Qian YY; Hong BF; Dou LP; Li L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jan; 26(1):13-7. PubMed ID: 20056079
[TBL] [Abstract][Full Text] [Related]
45. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
[TBL] [Abstract][Full Text] [Related]
46. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
[TBL] [Abstract][Full Text] [Related]
47. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function.
Hu CE; Gan J; Zhang RD; Cheng YR; Huang GJ
Scand J Gastroenterol; 2011 Feb; 46(2):156-64. PubMed ID: 20822377
[TBL] [Abstract][Full Text] [Related]
48. Molecular mechanisms of nano-selenium in mitigating hepatocellular carcinoma induced by N-nitrosodiethylamine (NDEA) in rats.
Ahmed HH; Khalil WK; Hamza AH
Toxicol Mech Methods; 2014 Dec; 24(8):593-602. PubMed ID: 25156538
[TBL] [Abstract][Full Text] [Related]
49. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.
Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW
Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216
[TBL] [Abstract][Full Text] [Related]
50. Efficient generation of highly immunocompetent dendritic cells from peripheral blood of patients with hepatitis C virus-related hepatocellular carcinoma.
Kitahara M; Mizukoshi E; Nakamoto Y; Mukaida N; Matsushima K; Kaneko S
Int Immunopharmacol; 2014 Aug; 21(2):346-53. PubMed ID: 24893118
[TBL] [Abstract][Full Text] [Related]
51. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
52. [The presence and the significance of CD4+CD25+ regulatory T cells in livers of patients with hepatocellular carcinoma].
Yang XH; Liu BR; Jiang HC
Zhonghua Gan Zang Bing Za Zhi; 2007 Apr; 15(4):279-82. PubMed ID: 17456316
[TBL] [Abstract][Full Text] [Related]
53. The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma.
Lee WC; Wu TJ; Chou HS; Yu MC; Hsu PY; Hsu HY; Wang CC
Surgery; 2012 Feb; 151(2):213-22. PubMed ID: 21975289
[TBL] [Abstract][Full Text] [Related]
54. Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection.
Zhou ZJ; Xin HY; Li J; Hu ZQ; Luo CB; Zhou SL
Cancer Immunol Immunother; 2019 Aug; 68(8):1223-1233. PubMed ID: 31201473
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?
Cany J; Tran L; Gauttier V; Judor JP; Vassaux G; Ferry N; Conchon S
Immunotherapy; 2011 Apr; 3(4 Suppl):32-4. PubMed ID: 21524167
[TBL] [Abstract][Full Text] [Related]
56. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway.
Shao Y; Lo CM; Ling CC; Liu XB; Ng KT; Chu AC; Ma YY; Li CX; Fan ST; Man K
Cancer Lett; 2014 Dec; 355(2):264-72. PubMed ID: 25301451
[TBL] [Abstract][Full Text] [Related]
57. Uptake of donor lymphocytes treated with 8-methoxypsoralen and ultraviolet A light by recipient dendritic cells induces CD4+CD25+Foxp3+ regulatory T cells and down-regulates cardiac allograft rejection.
Zheng DH; Dou LP; Wei YX; Du GS; Zou YP; Song JY; Zhu ZD; Cai M; Qian YY; Shi BY
Biochem Biophys Res Commun; 2010 May; 395(4):540-6. PubMed ID: 20394727
[TBL] [Abstract][Full Text] [Related]
58. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1
Ye L; Zhang Q; Cheng Y; Chen X; Wang G; Shi M; Zhang T; Cao Y; Pan H; Zhang L; Wang G; Deng Y; Yang Y; Chen G
J Immunother Cancer; 2018 Dec; 6(1):145. PubMed ID: 30526680
[TBL] [Abstract][Full Text] [Related]
59. Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma.
Shi Y; Song Q; Hu D; Zhuang X; Yu S
Biochem Biophys Res Commun; 2015 May; 461(1):109-14. PubMed ID: 25862952
[TBL] [Abstract][Full Text] [Related]
60. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
